Cargando…
P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429326/ http://dx.doi.org/10.1097/01.HS9.0000969892.81209.ff |
| _version_ | 1785090683963441152 |
|---|---|
| author | Oum, Muhamad Nanaa, Ahmad Mittapalli, Amrutha He, Rong Viswanatha, David Greipp, Patricia Nguyen, Phuong Jevremovic, Dragan Arana Yi, Cecilia M Foran, James Benga, Kebede Gangat, Naseema Mangaonkar, Abhishek Saliba, Antoine Patnaik, Mrinal Hogan, William Litzow, Mark Tefferi, Ayalew Shah, Mithun Alkhateeb, Hassan Al-Kali, Aref |
| author_facet | Oum, Muhamad Nanaa, Ahmad Mittapalli, Amrutha He, Rong Viswanatha, David Greipp, Patricia Nguyen, Phuong Jevremovic, Dragan Arana Yi, Cecilia M Foran, James Benga, Kebede Gangat, Naseema Mangaonkar, Abhishek Saliba, Antoine Patnaik, Mrinal Hogan, William Litzow, Mark Tefferi, Ayalew Shah, Mithun Alkhateeb, Hassan Al-Kali, Aref |
| author_sort | Oum, Muhamad |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429326 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104293262023-08-17 P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE Oum, Muhamad Nanaa, Ahmad Mittapalli, Amrutha He, Rong Viswanatha, David Greipp, Patricia Nguyen, Phuong Jevremovic, Dragan Arana Yi, Cecilia M Foran, James Benga, Kebede Gangat, Naseema Mangaonkar, Abhishek Saliba, Antoine Patnaik, Mrinal Hogan, William Litzow, Mark Tefferi, Ayalew Shah, Mithun Alkhateeb, Hassan Al-Kali, Aref Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429326/ http://dx.doi.org/10.1097/01.HS9.0000969892.81209.ff Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Oum, Muhamad Nanaa, Ahmad Mittapalli, Amrutha He, Rong Viswanatha, David Greipp, Patricia Nguyen, Phuong Jevremovic, Dragan Arana Yi, Cecilia M Foran, James Benga, Kebede Gangat, Naseema Mangaonkar, Abhishek Saliba, Antoine Patnaik, Mrinal Hogan, William Litzow, Mark Tefferi, Ayalew Shah, Mithun Alkhateeb, Hassan Al-Kali, Aref P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE |
| title | P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE |
| title_full | P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE |
| title_fullStr | P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE |
| title_full_unstemmed | P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE |
| title_short | P747: CLINICAL CHARACTERISTICS AND OUTCOME OF EZH2-MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE |
| title_sort | p747: clinical characteristics and outcome of ezh2-mutated myeloid neoplasms: mayo clinic experience |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429326/ http://dx.doi.org/10.1097/01.HS9.0000969892.81209.ff |
| work_keys_str_mv | AT oummuhamad p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT nanaaahmad p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT mittapalliamrutha p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT herong p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT viswanathadavid p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT greipppatricia p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT nguyenphuong p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT jevremovicdragan p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT aranayicecilia p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT mforanjames p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT bengakebede p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT gangatnaseema p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT mangaonkarabhishek p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT salibaantoine p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT patnaikmrinal p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT hoganwilliam p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT litzowmark p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT tefferiayalew p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT shahmithun p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT alkhateebhassan p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience AT alkaliaref p747clinicalcharacteristicsandoutcomeofezh2mutatedmyeloidneoplasmsmayoclinicexperience |